1 terminated, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Flex Pharma, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS FLX-787-ODT - Amyotrophic Lateral Sclerosis, Fasciculation | Phase 1 / Phase 2 | Terminated | Flex Pharma, Inc. | 3 | 2018-04-05 | 2018-08-29 |
| Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS FLX-787-ODT (orally disintigrating tablet) - Amyotrophic Lateral Sclerosis, Fasciculation | Phase 1 / Phase 2 | Withdrawn | Flex Pharma, Inc. | 2017-11-01 | 2018-01-23 |
Amyotrophic Lateral Sclerosis (2) · Fasciculation (2)
United States (2)